True Effects or Bias? MMP-2 and MMP-9 Serum Concentrations after Acute Stroke

Cerebrovascular Diseases

Volumn 42, Issue 5-6, 2016, Pages 352-360

  Kreisel, Stefan H ^a,b   Stroick, Mark ^c   Griebe, Martin ^a   Alonso, Angelika ^a   Reuter, Björn ^d   Hennerici, Michael G ^a   Fatar, Marc ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c Klinikum Memmingen   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute stroke; Bias; Biomarkers; Confounding; Epidemiology; Matrix metalloproteinases

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; GELATINASE A; GELATINASE B; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; UREA; BIOLOGICAL MARKER; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD LEVEL; BRAIN HEMORRHAGE; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ECHOENCEPHALOGRAPHY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TOBACCO DEPENDENCE; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; STATISTICAL BIAS; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIAS; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84976293833     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000446405     Document Type: Article

References (25)

1. Fatar M, Stroick M, Griebe M, Hennerici M: Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 2005; 20: 141-151.
2. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-633.
3. Reuter B, Rodemer C, Grudzenski S, Couraud PO, Weksler B, Romero IA, et al: Temporal profile of matrix metalloproteinases and their inhibitors in a human endothelial cell culture model of cerebral ischemia. Cerebrovasc Dis 2013; 35: 514-520.
4. Piccardi B, Palumbo V, Nesi M, Nencini P, Gori AM, Giusti B, et al: Unbalanced metalloproteinase-9 and tissue inhibitors of metalloproteinases ratios predict hemorrhagic transformation of lesion in ischemic stroke patients treated with thrombolysis: results from the MAGIC study. Front Neurol 2015; 6: 121.
5. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
6. Fitch MT, Doller C, Combs CK, Landreth GE, Silver J: Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammationinduced secondary injury after CNS trauma. J Neurosci 1999; 19: 8182-8198.
7. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, et al: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759-1766.
8. Montaner J, Rovira A, Molina CA, Arenillas JF, Ribó M, Chacón P, et al: Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 2003; 23: 1403-1407.
9. Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, et al: Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 2012; 30: 3-16.
10. Parks WC, Wilson CL, López-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-629.
11. Kreisel SH, Stroick M, Reuter B, Senn E, Hennerici MG, Fatar M: MMP-2 concentrations in stroke according to etiology: adjusting for enzyme degradation in stored deepfrozen serum and other methodological pitfalls. J Clin Neurosci 2012; 19: 1564-1567.
12. Rouy D, Ernens I, Jeanty C, Wagner DR: Plasma storage at-80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 2005; 338: 294-298.
13. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al: Baseline NIH stroke scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53: 126-131.
14. Schisterman EF, Cole SR, Platt RW: Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009; 20: 488-495.
15. Sauerbrei W, Royston P: Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J R Stat Soc Ser A Stat Soc 1999; 162: 71-94.
16. Rubin DB: Inference and missing data. Biometrika 1976; 63: 581-592.
17. Nagano M, Fukami K, Yamagishi S, Ueda S, Kaida Y, Matsumoto T, et al: Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Am J Nephrol 2009; 29: 109-115.
18. Madro A, Czechowska G, Slomka M, Celinski K, Szymonik-Lesiuk S, Kurzepa J: The decrease of serum MMP-2 activity corresponds to alcoholic cirrhosis stage. Alcohol 2012; 46: 155-157.
19. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004; 42: 121-131.
20. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J: MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-1126.
21. Mun-Bryce S, Rosenberg GA: Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18: 1163-1172.
22. Ramos-Fernandez M, Bellolio MF, Stead LG: Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2011; 20: 47-54.
23. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34: 2165-2170.
24. Zhao BQ, Ikeda Y, Ihara H, Urano T, Fan W, Mikawa S, et al: Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004; 103: 2610-2616.
25. Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM: Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003; 34:e48-e50.